Kalshi and Polymarket bets on clinical trials criticized as 'ghastly'

Researchers criticize betting on clinical trials via platforms like Kalshi and Polymarket, warning it could incentivize insider trading and interfere with drug development. The platforms defend themselves, saying they provide valuable information to patients, sparking a debate over the ethics and impact of such markets.